Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Integra Lifesciences (IART)
:IART
Holding IART?
Track your performance easily
IART Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.81 - $45.42
Previous CloseN/A
Volume73.30K
Average Volume (3M)532.51K
Market Cap
$1.79B
Enterprise Value$3.10B
Total Cash (Recent Filing)$102.06M
Total Debt (Recent Filing)$665.00M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Feb 19, 2025EPS Estimate
0.85Last Dividend Ex-Date
Jul 02, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding77,163,520
10 Day Avg. Volume545,466
30 Day Avg. Volume532,514
Standard Deviation0.11
R-Squared0.34
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.11
Price to Cash Flow (P/CF)19.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.73
Enterprise Value/Revenue2.00
Enterprise Value/Gross Profit3.50
Enterprise Value/Ebitda24.74
Forecast
1Y Price Target
$24.67Price Target Upside10.04% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering8
Integra Lifesciences News
PremiumCompany Announcements
Integra Lifesciences Implements New Severance Program for Executives
PremiumCompany Announcements
Integra LifeSciences Announces Q3 2024 Financial ResultsBulls Say, Bears Say
Bulls Say
Financial PerformanceSecond-quarter sales exceeded expectations, coming in ahead of guidance and beating consensus estimates, indicating robust financial health.
Leadership And GrowthA new CEO, Mojdeh Poul, with three decades of multi-divisional experience at companies like 3M, Medtronic, Boston Scientific, GE, and Teleflex, will take over, potentially driving stronger growth.
Operational SuccessThe recent Acclarent deal has exceeded initial expectations by $11 million, which should drive stronger growth ahead, particularly once operational headwinds abate.
Bears Say
Financial PerformanceStreet estimates for FY25 appear to be too high, suggesting a potential misalignment with management's preliminary guidance.
Regulatory IssuesA Warning Letter from the FDA was issued relating to quality system issues at several IART facilities.
Revenue And EarningsRevenue and EPS forecasts have been lowered, with current projections indicating a decline from previous estimates.
---
Ownership Overview
3.19% Insiders
30.97% Mutual Funds
0.18% Other Institutional Investors
38.00% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IART FAQ
What was Integra Lifesciences’s price range in the past 12 months?
Integra Lifesciences lowest stock price was $16.80 and its highest was $45.42 in the past 12 months.
What is Integra Lifesciences’s market cap?
Integra Lifesciences’s market cap is $1.79B.
When is Integra Lifesciences’s upcoming earnings report date?
Integra Lifesciences’s upcoming earnings report date is Feb 19, 2025 which is in 32 days.
How were Integra Lifesciences’s earnings last quarter?
Integra Lifesciences released its earnings results on Nov 04, 2024. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.02.
Is Integra Lifesciences overvalued?
According to Wall Street analysts Integra Lifesciences’s price is currently Undervalued.
Does Integra Lifesciences pay dividends?
Integra Lifesciences pays a Notavailable dividend of $3.184 which represents an annual dividend yield of N/A. See more information on Integra Lifesciences dividends here
What is Integra Lifesciences’s EPS estimate?
Integra Lifesciences’s EPS estimate is 0.85.
How many shares outstanding does Integra Lifesciences have?
Integra Lifesciences has 77,163,520 shares outstanding.
What happened to Integra Lifesciences’s price movement after its last earnings report?
Integra Lifesciences reported an EPS of $0.41 in its last earnings report, beating expectations of $0.39. Following the earnings report the stock price went up 25.104%.
Which hedge fund is a major shareholder of Integra Lifesciences?
Among the largest hedge funds holding Integra Lifesciences’s share is Sachem Head Capital Management LP. It holds Integra Lifesciences’s shares valued at 44M.
---
Integra Lifesciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$24.67 (10.04% Upside)
$24.67 (10.04% Upside)
Blogger Sentiment
Bullish
IART Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $141.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.66%
12-Months-Change
Fundamentals
Return on Equity
-0.42%
Trailing 12-Months
Asset Growth
8.73%
Trailing 12-Months
Company Description
Integra Lifesciences
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.
---
IART Company Deck
---
IART Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted a mix of positive developments, such as a promising leadership transition and strong demand in key segments, against significant challenges like revenue decline, supply chain issues, and reduced margins. The Acclarent acquisition's success was a bright spot, but overall, the company faces ongoing operational difficulties and compliance hurdles.Read More>---
IART Stock 12 Month Forecast
Average Price Target
$24.67
▲(10.04% Upside)
Technical Analysis
Alcon
―
Insulet
―
Smith & Nephew Snats
―
Stryker
―
Zimmer Biomet Holdings
―
Boston Scientific
―
Best Analysts Covering IART
1 Year
1 Year Success Rate
8/11 ratings generated profit
1 Year Average Return
+18.57%
reiterated a sell rating 12 days ago
Copying Craig Bijou's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +18.57% per trade.
---